RNA Platform

The unique components of AAHI’s RNA Platform allow us to rapidly design and manufacture highly potent and broadly effective vaccines in response to emerging disease. RNA vaccine and therapeutic candidates developed on AAHI’s immune-enhancing platform can be made readily accessible and available to all areas of the world.

AAHI’s RNA Platform uses antigen-generating self-amplifying RNA (saRNA) molecules fixed to the exterior of our proprietary nanostructured lipid carrier (NLC) nanoparticles.

Potent Immune Response:

saRNA amplifies antigen production and strengthens immune response. Squalene oil in the NLC core acts as an adjuvant, or immunostimulant.

Breadth of protection:

The saRNA/NLC vaccine complex can protect against multiple pathogen targets by using multivalent saRNA constructs, by loading NLC with multiple saRNA constructs aimed at different targets, or by administering a combination of monovalent complexed saRNA/NLC.

Accessibility and rapid pandemic response:

Vaccine candidates developed on our RNA Platform are available for use in low resource areas because the complexed saRNA/NLC is stable at room temperature for six months or at refrigerated temperatures for up to a year, eliminating deep cold chain requirements, and enabling alternative routes of delivery.

Because saRNA is bound to the outside of NLC, we can stockpile NLC, which can be stored and later complexed with saRNA to elicit production of whatever vaccine antigen is needed

Our RNA Platform enables development of equitably accessible vaccines and therapeutics to address unmet global needs.


IDRI offers world-class expertise in the design, formulation, and manufacture of vaccines, adjuvants, immunotherapies, and their components.

Research Material Supply
Our RNA team can evaluate our NLC delivery system with your RNA of choice.
RNA Construct Design
Our RNA team can express your antigen of interest using proven saRNA constructs.
Template DNA Synthesis
Our RNA team can clone desired self-amplifying RNA DNA templates to make RNA.
R&D-grade RNA Manufacture
Our RNA team can transcribe and purify RNA products in vitro.
Characterization Essays
Our RNA team can evaluate RNA quality and integrity of RNA and/or complexed RNA.
Stability Testing
Our RNA team can test the stability of RNA and/or complexed RNA products.
Immunogenicity Testing
Our RNA team can evaluate RNA vaccine immunogenicity in preclinical mouse models.

Other Services


AAHI provides consulting services for preclinical study development with the ability to get you directly into clinic and supply for your clinical trials with regulatory support.

Contact us to test AAHI adjuvant formulations with your vaccine antigen to develop a potent, durable, and broadly effective vaccine.